Spectrum's Pivotal BELIEF: PTCL Data 'Topo' the Mark
By Randy Osborne
Friday, December 21, 2012
Spectrum Pharmaceuticals Inc.'s endpoint-beating success in the pivotal Phase II study with belinostat for relapsed/refractory peripheral T-cell lymphoma keeps the firm on track potentially to pair the pan-histone deacetylase inhibitor with Spectrum's antifolate Folotyn, already approved for the condition.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.